Proliferation Signal Inhibitors in Transplantation: Questions at the Cutting Edge of Everolimus Therapy

Keyphrases

• Transplantation 100%
• Everolimus 100%
• Proliferation Signal Inhibitors 100%
• Immunosuppressive Therapy 50%
• Adverse Events 16%
• Surgeons 16%
• Immunosuppression 16%
• Nephrologists 16%
• Cardiovascular Disease 16%
• Patient Survival 16%
• Unmet Needs 16%
• Malignancy 16%
• Infectious Diseases 16%
• Antiproliferative Activity 16%
• Practical Guidance 16%
• Renal Transplantation 16%
• Long-term Complications 16%
• Graft Survival 16%
• Transplant Outcomes 16%
• Normal Rate 16%
• Sirolimus 16%
• Patient Morbidity 16%
• Long-stay Patients 16%
• Inhibitor Treatment 16%
• Patient Survival Rate 16%
• Cardiologists 16%
• Therapeutic Management 16%
• Heart Transplantation 16%
• Cardiac Allograft Vasculopathy 16%
• Clinical Potential 16%
• Long-term Graft Survival 16%
• Immunosuppressive Activity 16%
• Grafting Ratio 16%
• Patient Mortality 16%

Medicine and Dentistry

• Immunosuppressive Treatment 100%
• Everolimus 100%
• Base 25%
• Infection 25%
• Transplantation 25%
• Adverse Event 25%
• Surgeon 25%
• Survival Rate 25%
• Nephrologist 25%
• Cardiovascular Disease 25%
• Cancer 25%
• Kidney Transplantation 25%
• Allograft 25%
• Antiproliferative Activity 25%
• Immunosuppressive Drug 25%
• Acute Graft Rejection 25%
• Heart Transplantation 25%
• Therapeutic Management 25%
• Rapamycin 25%
• Cardiac Allograft Vasculopathy 25%

Immunology and Microbiology

• Everolimus 100%
• Immunosuppressive Therapy 100%
• Sirolimus 33%
• Survival Rate 33%
• Acute Graft Rejection 33%
• Immunosuppressive Drug 33%
• Antiproliferative Activity 33%
• Immunosuppression 33%
• Heart Transplantation 33%
• Renal Transplantation 33%
• Allograft Vasculopathy 33%
• Allograft 33%